U.S. markets close in 4 hours 1 minute

Sanofi (SAN.PA)

Paris - Paris Precio retrasado. Divisa en EUR.
Añadir a la lista de seguimiento
85.33-0.85 (-0.99%)
Al cierre: 5:35p.m. CEST

Sanofi

54, Rue La BoEtie
Paris 75008
France
33 1 53 77 40 00
http://www.sanofi.com

Sector(es)Healthcare
IndustriaDrug Manufacturers—General
Empleados a tiempo completo100,409

Ejecutivos clave

NombreTítuloPagarEjecutadoAño de nacimiento
Mr. Paul HudsonCEO & Director2.03MN/D1967
Mr. Jean-Baptiste Chasseloup de ChatillonExec. VP & CFON/DN/D1965
Mr. Laurent GilhodesPrincipal Accounting Officer and VP of Corp. AccountingN/DN/DN/D
Mr. Bruno MénardChief Information officerN/DN/DN/D
Mr. George Grofik C.F.A., CPA, CFAHead of Investor RelationsN/DN/DN/D
Los importes son a partir de 31 de diciembre de 2019 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Pago corresponde al salario, las bonificaciones, etc. Ejecutado corresponde al valor de las opciones ejecutadas durante el año fiscal. Divisa en EUR.

Descripción

Sanofi provides therapeutic solutions worldwide. It offers Cerezyme and Cerdelga for Gaucher, Myozyme and Lumizyme for Pompe, Fabrazyme for Fabry, and Aldurazyme for mucopolysaccharidosis Type 1; and Aubagio and Lemtrada for multiple sclerosis. It also provides Dupixent for atopic dermatitis; Kevzara for rheumatoid arthritis; Eloctate and Alprolix to treat hemophilia; and Cablivi to treat acquired thrombotic thrombocytopenic purpura. In addition, it offers Libtayo for metastatic cutaneous squamous cell carcinoma; Jevtana and Taxotere taxane for cancers; Eloxatin for colon cancer; Thymoglobulin, an immunosuppressive and immunomodulating agent; Mozobil for hematologic malignancies; and Zaltrap for metastatic colorectal cancer. Further, it provides Lantus, Toujeo, Apidra, and Insuman insulins; Amaryl sulfonylurea; Adlyxin/Lyxumia, a GLP-1 receptor agonist; Soliqua 100/33/Suliqua, an insulin glargine and lixisenatide combination to treat diabetes; Admelog/Insulin lispro insulin; Praluent, a cholesterol-lowering drug; and Multaq, an anti-arrhythmic drug for atrial fibrillation. Additionally, it offers Plavix for atherothrombotic conditions; Lovenox for the prophylaxis, venous thromboembolism, and acute coronary syndrome; Aprovel and CoAprovel anti-hypertensives; Renagel and Renvela for patients undergoing dialysis; Synvisc and Synvisc-One viscosupplements for osteoarthritis; Stilnox for insomnia; Allegra for seasonal allergic rhinitis and uncomplicated hives; and Depakine for epilepsy. It also provides generic products; and products for allergy, cough, cold, pain, nutrition, digestion, pediatrics, influenza, meningitis, travel, and endemic vaccines; and adult and adolescent boosters. Sanofi has collaborations with Verily Life Sciences LLC; Happify Health; GlaxoSmithKline Plc; and Kymera Therapeutics. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.

Gestión corporativa

La calificación ISS Governance QuickScore de Sanofi a partir del 9 de diciembre de 2019 es 2. Las puntuaciones principales son Auditoría: 1; Junta: 2; Derechos del accionista: 4; Compensación: 3.

Las puntuaciones de la gestión corporativa son cortesía de Servicios de accionistas institucionales (ISS). Las puntuaciones indican una posición decil en relación con el índice o la región. Una puntuación decil 1 indica que el riesgo de gestión es menor, mientras que una puntuación decil 10 indica que el riesgo de gestión es mayor.